文献速递浆细胞疾病

来那度胺末次剂量、疗程及无IMiD间期对泊马度胺/地塞米松治疗骨髓瘤的影响

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
PubMed 文献 · Blood Adv · 2019-01-01

该研究纳入147例连续接受泊马度胺/地塞米松(Pd)治疗的复发/难治多发性骨髓瘤患者,分析来那度胺耐药时剂量、暴露时长及无药间期对疗效的影响。结果显示,来那度胺末次剂量不影响缓解率,但来那度胺疗程≥12个月及无IMiD间期≥18个月与更高的缓解率和更长的PFS/OS相关。

核心结论

  • 来那度胺耐药时剂量不影响后续Pd疗效,但较长的来那度胺暴露及较长的无IMiD间期与更好的生存相关。

研究设计与样本

  • 回顾性分析147例连续接受泊马度胺/地塞米松(Pd)治疗的复发/难治多发性骨髓瘤患者,中位既往治疗线数为3。

主要发现

  • 意向性分析中33%患者达到≥部分缓解(PR)。
  • Pd紧随来那度胺后给药时≥PR率为32%,紧随硼替佐米后为37%。
  • 来那度胺疗程≥12个月组与<12个月组的≥PR率分别为44%和27%。
  • 无IMiD间期≥18个月组与<18个月组的≥PR率分别为65%和23%。

临床怎么用

  • 对于来那度胺耐药的多发性骨髓瘤患者,后续使用泊马度胺/地塞米松时,无需因既往来那度胺剂量较高而排除治疗。
  • 较长的来那度胺疗程和无IMiD间期≥18个月提示后续Pd治疗可能获得更好生存,可辅助临床决策。

局限性

  • 回顾性研究设计,样本量有限(147例),结果需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To gain insights into the characteristics of clinical resistance to lenalidomide, we evaluated the outcomes of 147 consecutive patients with multiple myeloma (MM) homogeneously treated with immunomodulatory imide drugs (IMiDs) pomalidomide and dexamethasone (Pd) for relapsed and/or refractory MM (median, 3 prior lines of treatment). We focused our analysis on the effect of the lenalidomide dose at which resistance was developed, the duration of lenalidomide exposure, and lenalidomide-free interval. On intent to treat, 33% of patients achieved ≥partial remission (PR) with Pd. When Pd was given immediately after lenalidomide, ≥PR was 32% (vs 37% after bortezomib). The response rates were similar for patients that received 5 to 15 mg vs 25 mg of lenalidomide (38.5% vs 30.5%, P = .329). Response rates were higher for patients that had received at least 12 months of lenalidomide (44% vs 27%) and for those with ≥18 months from last lenalidomide dose to pomalidomide dose (65% vs 23%). Median progression-free survival (PFS) and overall survival (OS) were 5 and 12.1 months, respectively, which was similar for patients who received lenalidomide, bortezomib or other regimens just before Pd and similar for patients who were receiving different doses of lenalidomide. IMiD-free interval ≥18 months was associated with longer PFS (10.3 vs 3.9 months, P = .003) and OS (27.1 vs 9.3, P = .008) as well as duration of last lenalidomide therapy ≥12 months (PFS: 7.8 vs 3.2, P = .023; OS: 16.5 vs 7.9, P = .005) even after adjustment for the number of prior therapies, duration of disease, and last lenalidomide dose.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kastritis E, Roussou M, Gavriatopoulou M, et al. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. Blood Adv. 2019. PMID: 31821457. doi:10.1182/bloodadvances.2019000539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。